02 October 2014 : Original article
Induction therapy, tacrolimus plasma concentration, and duration of intensive care unit stay are risk factors for peripheral leucopenia following heart transplantationTomasz UrbanowiczABCDEFG, Ewa Straburzyńska-MigajBDE, Aneta KlotzkaCE, Hanna Baszyńska-WachowiakBEF, Marcin MisterskiF, Stefan GrajekEF, Marek JemielityBCF
Ann Transplant 2014; 19:494-498
BACKGROUND: Although survival among heart recipients has increased, a limiting factor is chronic adverse effects of immunosuppression therapy.
MATERIAL AND METHODS: We performed a retrospective analysis of 22 patients (19 men and 3 women) with a mean age of 48±12 years who underwent orthotropic heart transplantation. There were 20 (91%) patients who received induction therapy (basiliximab, Simulect, Novartis Europharm Limited). All patients were treated with standard triple immunosuppressive regimen (tacrolimus, mycophenolate mofetil, and steroids).
RESULTS: Patients were divided into 2 groups according to postoperative peripheral cytopenia diagnosis. There were 16 (73%) in the cytopenic group and 6 (27%) in the non-cytopenic group. Mean time of peripheral leucopenia detection was 65±13 days following surgery. The blood leucocyte count was 0.98±0.2×10^3/mm3 vs. 5.85±0.9×10^3/mm3 in patients with peripheral cytopenia compared to non-cytopenic patients (p<0.01). There was a statistically important difference in duration of intensive care unit stay between the 2 groups (p<0.01). A correlation between tacrolimus serum concentration and risk for leucopenia was also detected (p<0.05).
CONCLUSIONS: Basiliximab administration as induction therapy, tacrolimus serum concentration, and duration of intensive care unit stay are risk factors for leucopenia.
Keywords: Antibodies, Monoclonal, Heart Transplantation, Intensive Care, Tacrolimus
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review articleNormothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588